Yazar "Koseoglu, Mesrure" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    A Multicenter Real-World Data of Cladribine Tablets in Patients with Multiple Sclerosis in Turkey
    (Sage Publications Ltd, 2023) Koseoglu, Mesrure; Omerhoca, Sami; Balci, Fatma Belgin; Unal, Aysun; Ozdemir, Zeynep; Yuksel, Burcu; Celik, Rabia Gokcen Gozubatik
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting
    (Elsevier Sci Ltd, 2023) Altunan, Bengu; Unal, Aysun; Efendi, Husnu; Koseoglu, Mesrure; Terzi, Murat; Kotan, Dilcan; Tamam, Yusuf
    Background: Follow-on disease modifying therapies (FO-DMTs) do not always require Phase III studies. There are concerns that cheaper FO-DMTs are only used to reduce healthcare costs. However, the well-being of people with MS (pwMS) should be a priority. We aimed to evaluate the efficacy, safety and treatment satisfaction of one of the FO-Fingolimod (FTY) used in Turkey with the approval of Turkish Ministry of Health.Methods: PwMS under FTY were recruited from 13 centers and real-world data and answers of satisfaction and adherence statements of pwMS on FTY treatment were analyzed.Results: Data of 239 pwMS were obtained. The duration of FTY treatment was 2.5 & PLUSMN; 0.8 (1-4) years in pwMS who were included in the study and whose treatment continued for at least one year. Significant decreases in annual relapse rate (p < 0.001), Expanded Disability Status Scale (p < 0.001) and neuroimaging findings (p < 0.001) were observed. While 64% of the patients were satisfied and 71.5% were found to adherent with this FO-FTY.Conclusion: This multicenter retrospective study found that the efficacy, safety and treatment adherence of a prescribed FO-FTY were consistent with the results of real-world studies. Studies including real-world data may provide guidance to address issues related to FO-FTY use.